iShares MSCI France ETF vs Novartis AG — how do they compare? iShares MSCI France ETF trades at $47.48, while Novartis AG trades at $152.6 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWQ | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $168.62 |
52-Week Low | $41.68 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Signals from Pluang's Aura AI — not financial advice
EWQ, the iShares MSCI France ETF, trades at $47.505, down 0.51% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on French equities, particularly industrials, and offers a dividend scheduled for June 2026. Recent news highlights ECB rate decisions and French tech investments, influencing sentiment.
The outlook for EWQ is supported by bullish technicals and positive analyst views on French stocks, but risks include ECB policy shifts and geopolitical tensions. Investors may find opportunity in Europe's cyclical recovery, though volatility from energy prices and economic data poses challenges.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →